-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HC Wainwright Lowers ProQR Therapeutics (NASDAQ:PRQR) Price Target to $1.50
HC Wainwright Lowers ProQR Therapeutics (NASDAQ:PRQR) Price Target to $1.50
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its price objective dropped by equities research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 71.62% from the company's previous close.
Several other research firms have also recently issued reports on PRQR. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target for the company in a research report on Friday. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.93.
Get ProQR Therapeutics alerts:ProQR Therapeutics Price Performance
Shares of NASDAQ PRQR opened at $0.87 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.18. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The company has a market cap of $62.31 million, a PE ratio of -0.86 and a beta of 0.80.
Institutional Trading of ProQR Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $80,000. Coastal Bridge Advisors LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $85,000. Daiwa Securities Group Inc. lifted its stake in shares of ProQR Therapeutics by 22.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 2,352 shares in the last quarter. Corton Capital Inc. acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $280,000. Finally, Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at about $48,000.ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its price objective dropped by equities research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 71.62% from the company's previous close.
据Benzinga报道，在周一发布的一份研究报告中，HC Wainwright的股票研究分析师将ProQR Treateutics(纳斯达克：PRQR-GET评级)的目标价格从2.00美元下调至1.5美元。该公司目前对这家生物制药公司的股票给予“买入”评级。HC Wainwright的目标价显示，该公司较前一交易日收盘价有71.62%的潜在上涨空间。
Several other research firms have also recently issued reports on PRQR. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target for the company in a research report on Friday. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.93.
其他几家研究公司最近也发布了关于PRQR的报告。在周五的一份研究报告中，Chardan Capital将ProQR治疗公司的评级从“买入”下调至“中性”。Raymond James在周五的一份研究报告中将ProQR治疗公司的评级从“市场表现”上调至“跑赢大盘”，并为该公司设定了2.00美元的目标价。在5月9日星期一的一份研究报告中，StockNews.com将ProQR治疗公司的评级从“卖出”上调为“持有”。最后，坎托·菲茨杰拉德在5月9日星期一的一份研究报告中重申了对ProQR治疗公司股票的“增持”评级。四名股票研究分析师对该股的评级为持有，五名分析师对该公司股票的评级为买入。根据MarketBeat的数据，该股的平均评级为“中等买入”，平均目标价为4.93美元。
ProQR Therapeutics Price Performance
ProQR治疗药物性价比
Shares of NASDAQ PRQR opened at $0.87 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.18. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The company has a market cap of $62.31 million, a PE ratio of -0.86 and a beta of 0.80.
周一，纳斯达克PRQR的股价开盘报0.87美元。该公司的债务权益比为0.43，流动比率为5.93，速动比率为5.93。该股的50日移动均价为0.80美元，200日移动均价为1.18美元。ProQR治疗公司的一年低点为0.53美元，一年高位为9.09美元。该公司市值为6,231万美元，市盈率为-0.86，贝塔系数为0.80。
Institutional Trading of ProQR Therapeutics
ProQR治疗药物的制度性交易
ProQR Therapeutics Company Profile
ProQR治疗公司简介
(Get Rating)
(获取评级)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物制药公司，致力于发现和开发基于RNA的治疗遗传疾病的疗法。它主要开发正处于II/III期临床试验的sepofarsen，用于治疗Leber先天性黑发10病的照明试验；以及正在进行II/III期临床试验的ultevursen，用于治疗USH2A介导的视网膜色素变性和USHER综合征。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- 免费获取StockNews.com关于ProQR治疗(PRQR)的研究报告
- 第二季度财报季最热门的五个电话
- 以下是一个简单的4只股票投资组合，它可以跑赢大盘
- AMC娱乐公司是在对猩猩采取快速行动吗？
- 以下是《降低通胀法案》如何提振电力库存
- 值得关注的两场重要的零售股大战
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProQR治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧